539 related articles for article (PubMed ID: 31936151)
21. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
22.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
23. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
24. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
[TBL] [Abstract][Full Text] [Related]
25. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D
Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
27. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
Marin-Bejar O; Rogiers A; Dewaele M; Femel J; Karras P; Pozniak J; Bervoets G; Van Raemdonck N; Pedri D; Swings T; Demeulemeester J; Borght SV; Lehnert S; Bosisio F; van den Oord JJ; Bempt IV; Lambrechts D; Voet T; Bechter O; Rizos H; Levesque MP; Leucci E; Lund AW; Rambow F; Marine JC
Cancer Cell; 2021 Aug; 39(8):1135-1149.e8. PubMed ID: 34143978
[TBL] [Abstract][Full Text] [Related]
28. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
29. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
30. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
33. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
[No Abstract] [Full Text] [Related]
35. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
36. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
37. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
38. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
39. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
40. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]